MedTrace Logo

ELO Water In Diabetes Care For Enhancement Of Blood Sugar Control

NCT04127890 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-01-27

No results posted yet for this study

Summary

This double-blinded, randomised and controlled trial evaluates the efficacy of oxygen-enriched ELO drinking water as an adjuvant modality in diabetes care for enhancement of glycemic control in patients with Type 2 diabetes mellitus. Adults with type 2 diabetes will be randomized to drink 1.5 L of either ELO water or normal drinking water for 24 weeks. The primary outcome is improvement in glycaemic control.

Conditions

Interventions

DIETARY_SUPPLEMENT

ELO Water

oxygen-enriched water

DIETARY_SUPPLEMENT

Placebo drinking water

bottled drinking water

Sponsors & Collaborators

  • ELO Water Pte. Ltd.

    collaborator INDUSTRY

  • Changi General Hospital

    lead OTHER

Principal Investigators

  • Joan Khoo, Dr · Changi General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-07
Primary Completion
2018-05-28
Completion
2018-05-28

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04127890 on ClinicalTrials.gov